Dirucotide Does Not Meet Primary Endpoint in Phase III Trial In Secondary Progressive MS

July 27, 2009 – Eli Lilly and Company and BioMS Medical Corp. today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as [...]

• Caroline says: BioMS and Lilly will now discontinue ongoing clinical trials with dirucotide and SPMS because dirucotide failed to meet its primary endpoint in a Ph 3 study. Bummer.
   

• Dirucotide (BioMS) Phase III U.S. Trial Gets Positive Safety Review From Data Safety Monitoring Board

  Edmonton, Alberta, April 14, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data [...]

  • Caroline says: Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (got that off BioMS website: www.biomsmedical.com). Dirucotide was developed specifically for people with secondary progressive MS.
     
  
  

  • SPMS Treatment Update: Spotlight on dirucotide (BioMS Medical Corp.)

    BioMS Medical Announces 2008 Year End Results Edmonton, Alberta, March 17, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis [...]

    • Caroline says: I think this is very positive news for people with SPMS because up until now, many of the therapies have been approved for, and more importantly, only WORK for those with RRMS. This is an encouraging update. They have initiated Phase III trials!